TrialJapanese journal of clinical oncology2025
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.
Lin Shen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.